
Sign up to save your podcasts
Or
This week's show had an all-star cast to review recent earnings. CannaVestments shared his thoughts on the federal and state-level catalysts in 2024 and contrasted this against eroding investor sentiment. He also gave his perspective on the recent results from GTI, Verano, and Trulieve.
Boris Jordan, Executive Chairman of Curaleaf, joined the show to review the company's Q4 2023 earnings. He also covered how 280E removal would benefit the business, the results of their recent institutional road show, and thoughts on the rapidly evolving hemp-derived cannabinoids business.
If you enjoyed this episode, please leave a five-star review on your favorite podcast platform. It helps new investors find the show and grows the cannabis-investing universe!
4.5
1111 ratings
This week's show had an all-star cast to review recent earnings. CannaVestments shared his thoughts on the federal and state-level catalysts in 2024 and contrasted this against eroding investor sentiment. He also gave his perspective on the recent results from GTI, Verano, and Trulieve.
Boris Jordan, Executive Chairman of Curaleaf, joined the show to review the company's Q4 2023 earnings. He also covered how 280E removal would benefit the business, the results of their recent institutional road show, and thoughts on the rapidly evolving hemp-derived cannabinoids business.
If you enjoyed this episode, please leave a five-star review on your favorite podcast platform. It helps new investors find the show and grows the cannabis-investing universe!
5,677 Listeners
591 Listeners
39 Listeners
1,985 Listeners
205 Listeners
2,050 Listeners
68 Listeners
45 Listeners
8,912 Listeners
460 Listeners
104 Listeners
31 Listeners
7 Listeners
6 Listeners
364 Listeners